CRMD
CorMedix Inc.
CRMD trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over CRMD overall, supported by stronger fundamentals and stronger modeled upside.
CRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
CRMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.5x | $2.52 | -48% |
| Fair | 3.9x | $2.83 | -41% |
| Current | 6.6x | $4.84 | — |
| Expensive | 18x | $13.42 | +177% |
Historical ranges are pointers, not guarantees.
CRMD's PE is in its expensive range at 6.6x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CRMD in the historical PE scenario, which offers more potential upside but is not a forecast.
CRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CRMD's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CRMD on the outlook, with more favorable earnings and revenue expectations.
CRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.73 | -65% |
| Q2 2026 | $2.18 | +179% |
| Q1 2026 | $2.17 | +768% |
| Q4 2025 | $2.04 | +$2.34 |
| Q3 2025 | $2.09 | +$2.89 |
| Q2 2025 | $0.78 | +$1.70 |
| Q1 2025 | $0.25 | +$1.17 |
| Q4 2024 | -$0.30 | +$0.61 |
CRMD has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.5M | -48% |
| Q2 2026 | $101.9M | +157% |
| Q1 2026 | $127.4M | +226% |
| Q4 2025 | $128.6M | +312% |
| Q3 2025 | $104.3M | +810% |
| Q2 2025 | $39.7M | +4829% |
| Q4 2022 | $29.7K | -47% |
| Q3 2022 | $6.8K | -82% |
CRMD's revenue is growing: $55M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -61 points |
| Q2 2026 | 42% | -7.1 points |
| Q1 2026 | 50% | -1.5 points |
| Q4 2025 | 46% | +4.5 points |
| Q3 2025 | 49% | +78 points |
| Q2 2025 | 49% | +1947 points |
| Q1 2025 | 52% | N/A |
| Q4 2024 | 41% | N/A |
CRMD's operating margin was −12% last quarter, down 61 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CRMD on profitability, with a higher operating margin.
CRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.8M | +189% |
| Q2 2026 | $85.7M | +186% |
| Q1 2026 | $41.7M | +111% |
| Q4 2025 | $92.7M | +$98.4M |
| Q3 2025 | $30.4M | +$44M |
| Q2 2025 | $30M | +$44M |
| Q1 2025 | $19.7M | +$37.1M |
| Q4 2024 | -$5.6M | +$5.4M |
CRMD has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
CRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -15% | -14M shares |
| 1 year | +9.1% | +6.5M shares |
| 3 years | +73% | +33.1M shares |
| 5 years | +106% | +40.4M shares |
| Available history | +225% | +54.3M shares |
CRMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $6.4M |
| Q1 2026 | $11.1M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -4.5x | Net Cash |
CRMD has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CRMD on leverage, with a lower net debt burden relative to earnings.
CRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 2.7 | Oversold |
CRMD's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CRMD PE vs Healthcare Sector
| Metric | CRMD | Sector median | Relative |
|---|---|---|---|
| PE | 6.6x | 26x | 74% below |
| PE % | 66 | 29 | 37 pts above |
CRMD has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.67 | 27% below |
| 20 week MA | $7.49 | 35% below |
| 50 week MA | $7.91 | 39% below |
| 100 week MA | $9.41 | 49% below |
| 200 week MA | $7.22 | 33% below |
CRMD is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CRMD on trend strength, trading above more of its moving averages.
CRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.14 | $7.87 | +10% |
| 2021 | $7.87 | $4.98 | -37% |
| 2022 | $4.98 | $4.11 | -17% |
| 2023 | $4.11 | $3.76 | -8.5% |
| 2024 | $3.76 | $8.21 | +118% |
| 2025 | $8.21 | $12.5 | +53% |
| 2026 YTD | $12.5 | $4.84 | -61% |
CRMD has finished lower in three of the last six years. It's down 61% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CRMD on returns for 2026, with the stronger performance.